OTCMKTS:VYNT Vyant Bio (VYNT) Stock Price, News & Analysis $0.19 +0.01 (+7.78%) As of 12/29/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Vyant Bio Stock (OTCMKTS:VYNT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vyant Bio alerts:Sign Up Key Stats Today's Range$0.18▼$0.2050-Day Range$0.19▼$0.1952-Week Range$0.14▼$1.58Volume19,100 shsAverage Volume161,822 shsMarket Capitalization$1.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewVyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). The company is based in Cherry Hill, New Jersey.Read More… Receive VYNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address VYNT Stock News HeadlinesVyant Bio files Certificate of Dissolution with State of DelawareDecember 26, 2023 | msn.comVyant Bio Inc VYNTDecember 19, 2023 | morningstar.comGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.June 17, 2025 | Investors Alley (Ad)Vyant Bio, Inc.: Vyant Bio Provides Update on Winddown ActivitiesNovember 11, 2023 | finanznachrichten.deVyant Bio expects to start liquidation payments in Q4 2024November 10, 2023 | msn.comVyant Bio Provides Update on Winddown ActivitiesNovember 10, 2023 | finance.yahoo.comVyant Bio, Inc.: Vyant Bio Announces Stockholder Approval of Plan of DissolutionNovember 1, 2023 | finanznachrichten.deVyant Bio shareholders approve plan to dissolve companyNovember 1, 2023 | msn.comSee More Headlines VYNT Stock Analysis - Frequently Asked Questions How have VYNT shares performed this year? Vyant Bio's stock was trading at $0.1940 at the start of the year. Since then, VYNT stock has increased by 0.0% and is now trading at $0.1940. View the best growth stocks for 2025 here. How were Vyant Bio's earnings last quarter? Vyant Bio, Inc. (OTCMKTS:VYNT) issued its earnings results on Thursday, November, 11th. The company reported ($0.75) earnings per share for the quarter, hitting the consensus estimate of ($0.75). The business earned $1.51 million during the quarter, compared to analyst estimates of $2.19 million. Vyant Bio had a negative trailing twelve-month return on equity of 151.82% and a negative net margin of 3,474.81%. Read the conference call transcript. When did Vyant Bio's stock split? Vyant Bio shares reverse split before market open on Wednesday, November 2nd 2022. The 1-5 reverse split was announced on Wednesday, November 2nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 2nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Vyant Bio? Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vyant Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vyant Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Alphabet (GOOG) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings11/11/2021Today6/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolOTCMKTS:VYNT CIK1349929 Webstemonix.com Phone(201) 479-1357Fax201-528-9201Employees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.69 million Net Margins-3,474.81% Pretax Margin-3,281.86% Return on Equity-151.82% Return on Assets-97.14% Debt Debt-to-Equity Ratio0.04 Current Ratio2.86 Quick Ratio2.86 Sales & Book Value Annual Sales$670 thousand Price / Sales1.83 Cash FlowN/A Price / Cash FlowN/A Book Value$1.69 per share Price / Book0.11Miscellaneous Outstanding Shares6,330,000Free Float5,724,000Market Cap$1.23 million OptionableNot Optionable Beta1.73 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (OTCMKTS:VYNT) was last updated on 6/17/2025 by MarketBeat.com Staff From Our PartnersThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWill I be blacklisted?The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vyant Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vyant Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.